A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food
Status:
Terminated
Trial end date:
2021-08-18
Target enrollment:
Participant gender:
Summary
The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced
Otezla® tablet formulations to assure comparability of results from Phase III trials of BI
730357 (new oral agent for treatment of psoriasis as well as other T helper 17 cells
(Th17)-mediated diseases) regardless of whether only the EU-sourced Otezla® or EU and
US-sourced Otezla®/Japan-sourced Otezla® have been used as an active comparator.